Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Praxis Precision Medicines, Inc. $PRAX

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 37,377 shares of Praxis Precision Medicines (≈$11.02 million), representing about 0.15% of the company at the end of the quarter.
• Analysts have a consensus "Buy" rating on PRAX with a consensus price target of $590.78 (five Strong Buy, twelve Buy, one Hold, two Sell).
• Praxis is a clinical‑stage biopharma with a market cap of $9.60 billion; it reported a quarterly EPS of -$3.50 (missing estimates) and its shares trade around $344.82 within a 12‑month range of $34.85–$356.00.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 37,377 shares of the company's stock, valued at approximately $11,016,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.15% of Praxis Precision Medicines at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRAX. GAMMA Investing LLC boosted its stake in Praxis Precision Medicines by 58.7% during the 4th quarter. GAMMA Investing LLC now owns 238 shares of the company's stock valued at $70,000 after purchasing an additional 88 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Praxis Precision Medicines by 24.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company's stock valued at $77,000 after purchasing an additional 359 shares during the period. AlphaQuest LLC raised its stake in shares of Praxis Precision Medicines by 1,623.3% in the 3rd quarter. AlphaQuest LLC now owns 1,999 shares of the company's stock worth $106,000 after buying an additional 1,883 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Praxis Precision Medicines by 60.0% in the fourth quarter. Farther Finance Advisors LLC now owns 368 shares of the company's stock valued at $108,000 after buying an additional 138 shares during the period. Finally, GF Fund Management CO. LTD. lifted its holdings in shares of Praxis Precision Medicines by 8.2% in the fourth quarter. GF Fund Management CO. LTD. now owns 490 shares of the company's stock valued at $144,000 after buying an additional 37 shares during the period. Institutional investors own 67.84% of the company's stock.

Analysts Set New Price Targets

PRAX has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $437.00 target price on shares of Praxis Precision Medicines in a report on Wednesday, April 15th. Wells Fargo & Company set a $305.00 price target on shares of Praxis Precision Medicines and gave the company an "equal weight" rating in a report on Friday, February 20th. HC Wainwright reaffirmed a "buy" rating and issued a $1,245.00 price objective on shares of Praxis Precision Medicines in a research note on Tuesday, April 7th. Citigroup reaffirmed a "conviction-buy" rating on shares of Praxis Precision Medicines in a research note on Tuesday, December 30th. Finally, Needham & Company LLC reissued a "buy" rating and set a $510.00 target price on shares of Praxis Precision Medicines in a research note on Tuesday, April 14th. Five equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $590.78.

Praxis Precision Medicines Price Performance

Shares of Praxis Precision Medicines stock opened at $344.82 on Monday. The stock's fifty day moving average is $318.32 and its 200-day moving average is $265.75. The firm has a market capitalization of $9.60 billion, a PE ratio of -25.62 and a beta of 2.94. Praxis Precision Medicines, Inc. has a 12-month low of $34.85 and a 12-month high of $356.00.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The company reported ($3.50) earnings per share for the quarter, missing analysts' consensus estimates of ($3.00) by ($0.50). Analysts expect that Praxis Precision Medicines, Inc. will post -14.88 EPS for the current year.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company's pipeline includes several lead candidates at various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.